(Q36349776)

English

Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. (English)

1 reference

Europe PubMed Central

13 August 2017

lymphoproliferative disorders

1 reference

based on heuristic

inferred from title

object named as

Karin A Thursky

1

0 references

object named as

Leon J Worth

2

0 references

object named as

Monica A Slavin

5

0 references

4

object named as

H Miles Prince

1 reference

Europe PubMed Central

13 August 2017

author name string

John F Seymour

3

1 reference

Europe PubMed Central

13 August 2017

language of work or name

0 references

publication date

1 January 2006

1 reference

Europe PubMed Central

13 August 2017

British Journal of Haematology

1 reference

Europe PubMed Central

13 August 2017

132

1 reference

Europe PubMed Central

13 August 2017

3-12

1 reference

Europe PubMed Central

13 August 2017

1

1 reference

Europe PubMed Central

13 August 2017

Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Prophylactic measures in the solid-organ recipient before transplantation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Alemtuzumab in T-cell malignancies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Hepatitis B virus reactivation and alemtuzumab therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Infectious complications of human T cell leukemia/lymphoma virus type I infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Guidelines on the diagnosis and management of chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Toxoplasma gondii infection in patients with hematological malignancies.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Septicemic complications of the cutaneous T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Towards a targeted, risk-based, antifungal strategy in neutropenic patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Chronic Strongyloides stercoralis infection in Laotian immigrants and refugees 7–20 years after resettlement in Australia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

The changing face of invasive fungal infections in hematopoietic cell transplant recipients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05789.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2005.05789.X

1 reference

Europe PubMed Central

13 August 2017

release_dyamzyx4k5fxhpj45ngmooawcq

1 reference

https://api.fatcat.wiki/v0/release/dyamzyx4k5fxhpj45ngmooawcq

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36349776&oldid=1856552203"